12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gilotrif afatinib regulatory update

FDA approved Gilotrif afatinib from Boehringer Ingelheim as first-line treatment for metastatic non-small cell lung cancer (NSCLC) in patients with an EGFR mutation...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >